Please ensure Javascript is enabled for purposes of website accessibility

4 Reasons Valeant Pharmaceuticals Int'l Inc. Nosedived 23% in March

By Sean Williams - Apr 4, 2017 at 3:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The laundry list of reasons to avoid Valeant keep piling up.

What happened

Shares of Valeant Pharmaceuticals (BHC -0.80%), the embattled drugmaker that's predominantly grown via acquisition over the past couple of years, tanked another 23% in March, according to data from S&P Global Market Intelligence. While there is a laundry list of issues with the company, four factors stood out for the March decline.

So what

The first issue for Valeant was its fourth-quarter results and guidance hangover. On the last day of February, Valeant announced its Q4 results and issued guidance for the 2017 year. In the fourth quarter, the company's Branded Rx drug segment saw sales slip 17%, while its bread and butter Bausch & Lomb operations saw revenue slip 1%. More importantly, Valeant called for just $3.55 billion to $3.7 billion in 2017 full-year EBITDA, which is only about two times more than what it'll pay to service the interest on its debt. That's worrisomely low.

Cash under lock and key.

Image source: Getty Images.

Secondly, and building on this first point, Valeant announced that it had completed a number of refinancing transactions in March. While Valeant does need all the flexibility it can get with its hefty debt load, every restructuring is coming with a price, either in the form of fees or higher interest rates. In effect, Valeant keeps buying more time and digging itself into a deeper hole.

Third, Valeant's main cheerleader, Bill Ackman, announced that his hedge fund, Pershing Square Capital Management, was raising the white flag and selling its remaining stake in the company. In total, Ackman's support of Valeant cost his hedge fund about $4 billion. Ackman waiving the white flag confirmed to investors just how much trouble Valeant is in.

And finally, as sort of the icing on the cake, former CEO J. Michael Pearson announced that he was suing the company over share-based compensation that he never received and alleges he is due. That compensation would be worth north of $30 million as of today. It's just another in a series of distractions for the once-mighty drug developer.

A businessman holding his hands up as if to say "no."

Image source: Getty Images.

Now what

And it gets worse folks – there's no simple fix.

Valeant's fourth-quarter report suggested that the company could grow its Branded Rx segment by 2% to 5% in 2017, yet this same segment just delivered a 17% year-over-year sales decline in Q4. The company's acquisition of Salix Pharmaceuticals in 2015 is also looking (thus far) like a terrible decision, and its new drug distribution partnership with Walgreens Boots Alliance appears to heavily favor Walgreens. In other words, even Valeant's reduced expectations may be too lofty.

Furthermore, Valeant is struggling mightily with its debt. The company needs to attract a certain premium to make selling its assets worthwhile, otherwise it'll merely be reducing its debt and making no headway on the all-important debt covenants that allow its lenders to sleep well at night. The company is pretty much in a no-win scenario.

With few redeeming qualities and no sign of a near-term turnaround, Valeant is a stock to continue to avoid. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
$8.68 (-0.80%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.